XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.

XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.
A
A

AstraZeneca

Savdo gʻoyalari

Treyderlarning kayfiyati

Texnik xulosa

Soatlik

Yangiliklar

Reuters - 1 kun oldin

US natural gas prices drop to 7-week low on rising output, high storage levels

UPDATE 1-US natural gas prices drop to 7-week low on rising output, high storage levels Adds latest prices July 5 (Reuters) - U.S. natural gas futures slipped over 4% to a seven-week low on Friday, as rising output and ample gas supply in storage outweighed support from forecasts for higher demand over the next two weeks. Front-month gas futures NGc1 for August delivery on the New York Mercantile Exchange fell 9.5 cents , to settle at $2.31 9 per million British thermal units (mmBtu).
A
Reuters - 1 kun oldin

US natural gas prices drop to 7-week low on rising output, high storage levels

US natural gas prices drop to 7-week low on rising output, high storage levels July 5 (Reuters) - U.S. natural gas futures slipped nearly 2% to a seven-week low on Friday, as rising output and ample gas supply in storage outweighed support from forecasts for higher demand over the next two weeks. Front-month gas futures NGc1 for May delivery on the New York Mercantile Exchange were down 4.6 cents, or 1.9%, to $2.37 per million British thermal units (mmBtu) at 10:57 a.m.
A
N
Reuters - 2 kun oldin

Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial

BUZZ-Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial Updates ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN
A
R
Reuters - 2 kun oldin

Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial

BUZZ-Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN has colo
A
R
Reuters - 2 kun oldin

AstraZeneca Says Tagrisso With Addition Of Chemotherapy Approved In EU

BRIEF-AstraZeneca Says Tagrisso With Addition Of Chemotherapy Approved In EU July 5 (Reuters) - AstraZeneca PLC AZN.L : TAGRISSO WITH THE ADDITION OF CHEMOTHERAPY APPROVED IN THE EU AS NEW 1ST-LINE TREATMENT FOR PATIENTS WITH EGFR-MUTATED ADVANCED LUNG CANCER SAFETY PROFILE OF TAGRISSO PLUS CHEMOTHERAPY CONSISTENT WITH ESTABLISHED PROFILES OF INDIV
A

Shartlar

Ommabop aktivlar

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.

Riskdan ogohlantirish: Kapitalingiz risk ostida. Kredit yordamiga ega mahsulotlar hammaga ham toʻgʻri kelmasligi mumkin. Bizning Risklardan ogohlantirishimiz bilan tanishib chiqing.